PALO
ALTO, Calif., April 29,
2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:
KOD), a biopharmaceutical company committed to researching,
developing and commercializing transformative therapeutics to treat
high prevalence retinal diseases, today announced that
presentations of clinical study data on its investigational therapy
KSI-301 will be made at two upcoming vision research conferences:
the Association for Research in Vision and Ophthalmology (ARVO)
2022 Annual Meeting in Denver,
Colorado, and Retina World Congress 2022 in Fort Lauderdale, Florida.
Details of the presentations are as follows:
ARVO:
Title: Efficacy, durability and safety of
KSI-301 antibody biopolymer conjugate in wet AMD – Primary results
of the Phase 2b/3 DAZZLE study
Presenter: Carl Regillo, M.D., Chief
of Retina Service, Wills Eye Hospital / Thomas
Jefferson University, Philadelphia, PA
Presentation date and time: May 3,
2022; 6:38 PM EDT
Retina World Congress:
Title: Results of the KSI-301
DAZZLE Neovascular AMD Pivotal Clinical Trial
Presenter: Carl Regillo, M.D., Chief
of Retina Service, Wills Eye Hospital / Thomas
Jefferson University, Philadelphia, PA
Presentation date and time: May 13,
2022; 5:14 PM EDT
Kodiak plans to post the slides from these presentations on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ following each presentation.
About KSI-301
KSI-301 is an investigational anti-VEGF
therapy built on Kodiak's Antibody Biopolymer Conjugate (ABC)
Platform and is designed to maintain potent and effective drug
levels in ocular tissues for longer than existing available agents.
Kodiak's objective with KSI-301 is to develop a new first-line
agent to improve outcomes for patients with retinal vascular
diseases and to enable earlier treatment and prevention of vision
loss for patients with diabetic eye disease. The KSI-301 clinical
program is designed to assess KSI-301's durability, efficacy and
safety in wet age-related macular degeneration (wet AMD), diabetic
macular edema (DME), retinal vein occlusion (RVO), and
non-proliferative diabetic retinopathy (NPDR) without DME through
clinical studies run in parallel. The Company's DAYLIGHT pivotal
study in patients with treatment-naïve wet AMD, GLEAM and GLIMMER
pivotal studies in patients with diabetic macular edema, and the
BEACON pivotal study in patients with retinal vein occlusion are
anticipated to form the basis of the Company's initial BLA to
support potential approval and commercialization in multiple
indications and with a full range of labeled and reimbursable
dosing frequencies. An additional Phase 3 pivotal study, GLOW, in
patients with non-proliferative diabetic retinopathy is also
underway. The global KSI-301 clinical program is being conducted at
150+ study sites in more than 10 countries. Kodiak is developing
KSI-301 and owns global rights to KSI-301.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a
biopharmaceutical company committed to researching, developing and
commercializing transformative therapeutics to treat high
prevalence retinal diseases. Founded in 2009, we are focused on
bringing new science to the design and manufacture of next
generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our ABC Platform™ uses molecular
engineering to merge the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including wet age-related
macular degeneration, the leading cause of blindness in elderly
patients in the developed world, and diabetic eye diseases, the
leading cause of blindness in working-age patients in the developed
world. Kodiak has leveraged its ABC Platform to build a pipeline of
product candidates in various stages of development including
KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the
treatment of neovascular retinal diseases with an inflammatory
component, and we are expanding our early research pipeline to
include ABC Platform based triplet inhibitors for multifactorial
retinal diseases such as dry AMD and glaucoma. Kodiak is based in
Palo Alto, CA. For more
information, please visit www.kodiak.com.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-announces-presentation-of-ksi-301-phase-2b3-study-data-in-wet-amd-at-upcoming-research-conferences-301536043.html
SOURCE Kodiak Sciences Inc.